{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Treatment', 'Restriction', 'NSAIDs', 'Initiation of new NSAIDs is prohibited during the first 12 weeks of the', 'OLE study.', 'Stable doses of NSAIDs are permitted during the first 12 weeks of', 'the OLE study if the subject received these NSAIDs during the core', 'study (see Section 6.13.2). Dose tapering is permitted according', 'to Investigator discretion; other changes in dose are prohibited', 'unless the Investigator changes the dose for safety reasons.', 'Switching of NSAIDs is not allowed. However, if the subject has', 'an AE that requires discontinuation of the NSAID, an alternative', 'NSAID may be initiated per the local label (if not contraindicated).', 'After the first 12 weeks of the OLE study (i.e., after Visit 4 [Week 36]),', 'dose modification and switching of NSAIDs is permitted (see', 'Section 6.13.3), per Investigator discretion and local guidelines.', 'Aspirin use at daily doses up to 325 mg is permitted throughout the', 'study if indicated for CV protection. At this dose, aspirin will not be', 'considered an NSAID.', 'Analgesics', 'Analgesics, including opioids, are prohibited during the first 12 weeks of', 'the OLE study with the following exception (see Section 6.13.2):', 'Paracetamol/acetaminophen: Maximum 2000 mg per day', '(maximum 1000 mg per dose). Paracetamol/acetaminophen are not', 'to be taken within 24 hours prior to joint assessment, including', 'OLE Baseline assessment.', 'After the first 12 weeks of the OLE study (i.e., after Visit 4 [Week 36]),', 'analgesics and opioids are permitted.', 'Hyaluronic acid', 'Intra-articular hyaluronic acid is prohibited during the first 12 weeks of', 'the OLE study.', 'After the first 12 weeks of the OLE study (i.e., after Visit 4 [Week 36]),', 'IA hyaluronic acid is permitted.', 'Joints that receive IA hyaluronic acid should be omitted from all', 'subsequent joint assessments (Sections 7.1.2, 7.1.6, and 7.1.7) and', 'should be rated with their pre-injection status for the remainder of', 'the study.', 'Vaccination', 'Live and live attenuated vaccines are prohibited during the entire study.', 'Abbreviations: bDMARD = biologic disease-modifying anti-rheumatic drug; cDMARD = conventional', 'disease-modifying anti-rheumatic drug; CV = cardiovascular; IA = intra-articular; MTX = methotrexate;', 'NSAID = non-steroidal anti-inflammatory drug; OLE = open-label extension.', '6.13.1', 'Olokizumab Potential Impact on Cytochrome P and Transporter Pathways', \"Based on nonclinical data (refer to the most recent version of the Investigator's Brochure), it\", 'is possible that OKZ may reverse IL-6-mediated inhibition of CYP or transporter pathways', 'such as CYP1A1/2, 2B6, 2C9, 3A4/5, and 2C19 and sodium/taurocholate co-transporting', 'polypeptide. If CYP or transporter activity is de-suppressed (i.e., increased to any relevant', 'extent), this may result in decreased level of drugs eliminated by these pathways. As such,', 'OKZ may have clinical relevance for CYP substrates with narrow therapeutic index and for', 'Amendment 2: 06 March 2019', '86', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'which a change in effectiveness may be undesirable. Investigators are advised to monitor', 'substrates with a narrow therapeutic index (as noted in their respective package inserts/drug', 'labels) and to contact the Medical Monitor to discuss any potential concerns about', 'concomitant medications.', '6.13.2', 'Allowed Medications', 'The following medications are allowed (non-exhaustive list), including clarifications of the', 'above prohibited medications:', 'Inhaled corticosteroids', 'Topical corticosteroids', 'Oral corticosteroids', '-', 'Doses of <10 mg/day of prednisone or equivalent are permitted during the first', '12 weeks of the OLE study, with dose tapering permitted according to Investigator', 'discretion. Other dose adjustments are not permitted during the first 12 weeks of the', 'OLE study unless the Investigator changes the dose for safety reasons.', '- Dose modification is permitted after Visit 4 (Week 36) (see Section 6.13.3), per the', \"Investigator's discretion and local practice, including transient dose increases with\", 'dose tapering as soon as possible after the dose increase.', '- Investigator should take into consideration the AEs associated with the continuous', 'use of corticosteroids (e.g., diabetes mellitus, infections, GI perforations)', 'IM or IV corticosteroids', '- Permitted after Visit 4 (Week 36) (see Section 6.13.3)', 'Intra-articular (IA) corticosteroids', '- Permitted in a maximum of 3 joints within the study period, not to exceed one', 'injection every 6 months. The cumulative dose for the 3 injections must not exceed', '40 mg methylprednisolone or equivalent. Joints treated with IA corticosteroids must', 'be rated with their pre-injection status for the remainder of the study and should be', 'omitted from all subsequent joint assessments (see Sections 7.1.2, 7.1.6, and 7.1.7).', 'Intra-articular hyaluronic acid', '- Permitted after Visit 4 (Week 36). Joints treated with IA hyaluronic acid must be', 'rated with their pre-injection status for the remainder of the study and should be', 'omitted from all subsequent joint assessments (see Sections 7.1.2, 7.1.6, and 7.1.7).', 'Amendment 2: 06 March 2019', '87', 'Confidential']\n\n###\n\n", "completion": "END"}